Seres Therapeutics (NASDAQ:MCRB) Share Price Crosses Above 50 Day Moving Average – Time to Sell?

Seres Therapeutics, Inc. (NASDAQ:MCRB) crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.81 and traded as high as $0.85. Seres Therapeutics shares last traded at $0.83, with a volume of 1,538,519 shares.

Analyst Ratings Changes

Several research firms recently weighed in on MCRB. StockNews.com lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 27th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $10.00 price target on shares of Seres Therapeutics in a research note on Thursday, November 14th. Chardan Capital restated a “buy” rating and issued a $1.25 target price on shares of Seres Therapeutics in a research note on Wednesday, November 13th. Finally, JPMorgan Chase & Co. downgraded Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. According to MarketBeat, Seres Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $5.08.

Seres Therapeutics Stock Up 7.4 %

The company has a market cap of $154.59 million, a price-to-earnings ratio of -3.94 and a beta of 2.07. The business has a 50-day simple moving average of $0.82 and a two-hundred day simple moving average of $0.90.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC grew its holdings in shares of Seres Therapeutics by 44.8% during the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 18,191 shares during the last quarter. Providence Wealth Advisors LLC boosted its position in shares of Seres Therapeutics by 49.5% during the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 25,250 shares in the last quarter. Point72 DIFC Ltd bought a new stake in shares of Seres Therapeutics in the 2nd quarter valued at $64,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Seres Therapeutics during the 2nd quarter worth $92,000. Finally, State Street Corp increased its holdings in shares of Seres Therapeutics by 12.9% in the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after acquiring an additional 43,700 shares in the last quarter. 59.34% of the stock is owned by institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.